olmesartan

Olmesartan (RNH 6270) 是一种血管紧张素 II 受体 (AT1R) 拮抗剂，常用于研究高血压。

Dehydro Olmesartan, deriving from Olmesartan, acts as an angiotensin II receptor (AT1R) antagonist and exhibits potential for the study of high blood pressure [1][2].

Olmesartan medoxomil impurity C is an Olmesartan medoxomil impurity. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM. [1]. Senda A, et al. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8. Biol Pharm Bull. 2015;38(12):1975-9. [2]. Shah S, et al. Simultaneous Quantitative Analysis of Olmesartan Medoxomil and Amlodipine Besylate in Plasma by High-performance Liquid Chromatography Technique. J Young Pharm. 2012 Apr;4(2):88-94.

Olmesartan methyl ester is an intermediate in the synthesis of Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor antagonist.

Olmesartan ethyl ester (compound 11) 是 Olmesartan 的一个杂质。Olmesartan (RNH-6270) 是血管紧张素 II 受体 (AT1R) 拮抗剂，可用于高血压研究。

Trityl olmesartan medoxomil impurity II为Trityl olmesartan medoxomil的杂质，后者是Olmesartan medoxomil的中间体。

Olmesartan Medoxomil (Benicar) 是血管紧张素 (angiotensin AT1) 受体选择性抑制剂(IC50:66.2 μM)。

Olmesartan D4 is the deuterium labeled Olmesartan. Olmesartan is an antagonist of angiotensin II receptor (AT1R) used to treat high blood pressure.

Olmesartan impurity, a compound related to Olmesartan, is an angiotensin II receptor (AT1R) antagonist utilized in the study of high blood pressure. Olmesartan (RNH-6270) is the parent compound with similar properties and functions as an AT1R antagonist.

Olmesartan lactone impurity is a cyclic ester impurity derived from Olmesartan, which is an angiotensin II receptor (AT1R) antagonist with potential applications in the study of high blood pressure.

Olmesartan-d6 Acid 是 Olmesartan Acid 的氘代化合物。Olmesartan Acid 的 CAS 号为 144689-24-7。Olmesartan 是一种血管紧张素II受体 (AT1R) 拮抗剂，常用于研究高血压。

Tritylolmesartan medoxomil is an intermediate in the synthesis of olmesartan medoxomil , a prodrug form of the angiotensin II receptor 1 (AT1) antagonist olmesartan .1 1.Hanumantha Rao, B., Subramanyeswara Rao, I.V., Ravi Kanth, V., et al.A competent and commercially viable process for the synthesis of the anti-hypertensive drug olmesartan medoxomilSci. Pharm.83(3)465-478(2015)